Journal

Haematologica

1592-8721 · Ferrata Storti Foundation (Haematologica)

40 verified public works

Browse all journals →

Response to Comment on: “Decreasing excess mortality after allogeneic stem cell transplantation for acute leukemia”

2026 · 0 citations

Salvage of primary graft failure with allogeneic hematopoietic stem cell transplantation from a deceased organ donor: report of a novel graft source

2026 · 0 citations

Philadelphia chromosome-like acute lymphoblastic leukemia: treat intensively, transplant selectively

2026 · 0 citations

The role of CHIP and pre-treatment neutropenia in patients treated with chimeric antigen receptor T cells for hematological malignancies

2026 · 0 citations

Measurable residual disease-negative remission of BRAF-V600Emutated acute myeloid leukemia with dabrafenib and trametinib

2026 · 0 citations

CD25-based graft-versus-host disease prophylaxis after haploidentical hematopoietic stem cell transplantation: comparison of two prophylactic strategies

2026 · 0 citations

Teclistamab desensitization of donor-specific antibodies in aplastic anemia

2026 · 0 citations

Beyond venetoclax and azacitidine: CD70-targeted triplet therapy in acute myeloid leukemia

2026 · 0 citations

β-thalassemia as a progressive disease: age-related morbidity in the de-LIGHT study

2026 · 0 citations

Five-year results of short-course brentuximab vedotin combined with chemotherapy and radiation in early stage, unfavorable Hodgkin lymphoma

2026 · 0 citations

Allogeneic hematopoietic stem cell transplantation rather than specific front-line therapy is associated with long-term survival in blastic plasmacytoid dendritic cell neoplasm: the Mayo Clinic experience

2026 · 0 citations

Response to Comment on: “Fibrinogen promotes acute myelogenous leukemia progression via miR-486/GPR153 axis”

2026 · 0 citations

Targeting leukemia stem cells in unfit acute myeloid leukemia with a CD70-directed third agent: promise and caveats from the ELEVATE trial. Comment on: “Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study”

2026 · 0 citations

BTK/BCL2 dual targeting enhances apoptosis in marginal zone lymphoma: preclinical activity of tacabrutideg (BGB-16673) and sonrotoclax

2026 · 0 citations

Heterogeneity in access to clinical trials for innovative hemophilia treatments: a call for global equity

2026 · 0 citations

Erratum to: “Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia”

2026 · 0 citations

Erratum to: “The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients”

2026 · 0 citations

Where would immune thrombocytopenia be without intravenous gammaglobulin?

2026 · 0 citations

Real-world minimal residual disease assessment in multiple myeloma using a standardized flow cytometry approach: feasibility, clinical implications, and immune correlates from a single-center experience

2026 · 0 citations

Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study

2026 · 0 citations

Single-cell RNA editing identifies aggressive and favorable cellular states in chronic myelomonocytic leukemia

2026 · 0 citations

Interleukin-17-associated inflammation in non-responders and B-cell remodeling after daratumumab in refractory immune thrombocytopenia

2026 · 0 citations

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma

2026 · 0 citations

Gilteritinib plus azacitidine in patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia who were ineligible for intensive chemotherapy: final results of the phase III LACEWING study

2026 · 0 citations

Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in adult acute myeloid leukemia patients: an analysis of ECOG-ACRIN clinical trials

2026 · 0 citations

Independent prognostic value of semaphorin-4D, interleukin-1β and complement activation in newly diagnosed multiple myeloma patients

2026 · 0 citations

Exposure-response and dose simulation of belantamab mafodotin in combination with standards of care in patients with relapsed/refractory multiple myeloma

2026 · 0 citations

Real-world experience with IDH inhibitors in pediatric patients with IDH1- and IDH2-mutated acute myeloid leukemia and myelodysplastic syndrome

2026 · 0 citations

Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: the association of JACIE accreditation/preparation and center volume

2026 · 0 citations

Homeostatic imbalance between von Willebrand factor and ADAMTS13 on hemorrhagic shock-induced endotheliopathy

2026 · 0 citations